

Susanna A Mccolley

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7584491/susanna-a-mccolley-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

6,927
citations

36
h-index

83
g-index

124
ext. papers

8,452
ext. citations

7.4
avg, IF

5.74
L-index

#	Paper	IF	Citations
106	Lumacaftor-ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. <i>New England Journal of Medicine</i> , 2015 , 373, 220-31	59.2	910
105	Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. <i>Pediatrics</i> , 2002 , 109, 704-12	7.4	753
104	Inability of clinical history to distinguish primary snoring from obstructive sleep apnea syndrome in children. <i>Chest</i> , 1995 , 108, 610-8	5.3	502
103	Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. <i>Journal of Pediatrics</i> , 2017 , 181S, S4-S15.e1	3.6	368
102	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 527-38	35.1	309
101	Respiratory compromise after adenotonsillectomy in children with obstructive sleep apnea. <i>JAMA Otolaryngology</i> , 1992 , 118, 940-3		287
100	Clinical significance of microbial infection and adaptation in cystic fibrosis. <i>Clinical Microbiology Reviews</i> , 2011 , 24, 29-70	34	271
99	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 539-47	35.1	242
98	Upper airway collapsibility in children with obstructive sleep apnea syndrome. <i>Journal of Applied Physiology</i> , 1994 , 77, 918-24	3.7	197
97	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 557-567	35.1	176
96	High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. <i>Chest</i> , 1997 , 111, 170-3	5.3	163
95	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 524-33	35.1	161
94	Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 298-306	10.2	158
93	Type III secretion phenotypes of <i>Pseudomonas aeruginosa</i> strains change during infection of individuals with cystic fibrosis. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 5229-37	9.7	154
92	Airway microbiota across age and disease spectrum in cystic fibrosis. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	113
91	Ivacaftor treatment of cystic fibrosis in children aged 12 to . <i>Lancet Respiratory Medicine</i> , 2018 , 6, 545-553	35.1	112
90	Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 171-8	10.2	97

89	Tolerance of 7% Hypertonic Saline in Pediatric Cystic Fibrosis Patients. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020 , 33, 63-68	0.8	78
88	Lung function decline from adolescence to young adulthood in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2012 , 47, 135-43	3.5	77
87	Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. <i>Journal of Pediatrics</i> , 2009 , 155, 634-9.e1-4	3.6	73
86	Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. <i>Pediatrics</i> , 2002 , 109, e67	7.4	73
85	Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000 , 161, 1877-80	10.2	72
84	Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2011 , 46, 36-44	3.5	69
83	Polysomnographic characteristics of patients with Rett syndrome. <i>Journal of Pediatrics</i> , 1994 , 125, 218-246	3.6	68
82	Polysomnography after adenotonsillectomy in mild pediatric obstructive sleep apnea. <i>Critical Care Medicine</i> , 1996 , 24, 1323-7	1.4	65
81	Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 325-335	35.1	63
80	Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1144-1151	10.2	61
79	Diagnosis of Cystic Fibrosis in Screened Populations. <i>Journal of Pediatrics</i> , 2017 , 181S, S33-S44.e2	3.6	60
78	Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 213-219	4.7	57
77	Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. <i>Pediatrics</i> , 2015 , 135, e1386-92	7.4	52
76	Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. <i>Pediatrics</i> , 2007 , 119, e531-7	7.4	48
75	EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. <i>Journal of Cystic Fibrosis</i> , 2009 , 8, 405-17	4.1	47
74	Immune response to influenza vaccination in children with renal disease. <i>Pediatric Nephrology</i> , 1995 , 9, 566-8	3.2	46
73	Risk factors for mortality before age 18 years in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2017 , 52, 909-915	3.5	44
72	Polysomnography in the evaluation of readiness for decannulation in children. <i>JAMA Otolaryngology</i> , 1996 , 122, 721-4		38

71	Evolution of <i>Pseudomonas aeruginosa</i> type III secretion in cystic fibrosis: a paradigm of chronic infection. <i>Translational Research</i> , 2008 , 152, 257-64	11	36
70	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 802-809	35.1	34
69	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1812-1816	11.6	33
68	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. <i>Journal of Pediatrics</i> , 2016 , 169, 116-21.e2	3.6	33
67	Pancreatic enzyme replacement therapy dosing and nutritional outcomes in children with cystic fibrosis. <i>Journal of Pediatrics</i> , 2014 , 164, 1110-1115.e1	3.6	32
66	Aminoglycoside resistance of <i>Pseudomonas aeruginosa</i> in cystic fibrosis results from convergent evolution in the mexZ gene. <i>Thorax</i> , 2017 , 72, 40-47	7.3	30
65	Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. <i>Pediatric Pulmonology</i> , 2009 , 44, 594-601	3.5	30
64	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One Allele. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 1522-1532	10.2	30
63	Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review. <i>International Journal of Eating Disorders</i> , 2018 , 51, 187-213	6.3	29
62	The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis. <i>Journal of Pediatrics</i> , 2010 , 157, 1035-7	3.6	29
61	Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 1721-1725	4.7	28
60	The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 1305-1311	4.1	27
59	Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. <i>Journal of Pediatrics</i> , 2011 , 159, 819-824.e1	3.6	27
58	Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV ₁ . <i>Journal of Cystic Fibrosis</i> , 2019 , 18, 94-101	4.1	26
57	Refining the continuum of CFTR-associated disorders in the era of newborn screening. <i>Clinical Genetics</i> , 2016 , 89, 539-49	4	24
56	Parental understanding of newborn screening for cystic fibrosis after a negative sweat-test. <i>Pediatrics</i> , 2011 , 127, 276-83	7.4	22
55	A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. <i>Respiratory Care</i> , 2007 , 52, 258-62	2.1	22
54	Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	21

53	Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition. <i>Journal of Cystic Fibrosis</i> , 2019 , 18, 778-780	4.1	17
52	Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis. <i>Scientific Reports</i> , 2019 , 9, 15483	4.9	17
51	Trichosporon mycotoxinivorans infection in patients with cystic fibrosis. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 2242-4	9.7	17
50	Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. <i>Pediatric Pulmonology</i> , 2021 , 56, 1496-1503	3.5	16
49	A safety evaluation of ivacaftor for the treatment of cystic fibrosis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 709-15	4.1	15
48	Energy metabolism during anaerobic exercise in children with cystic fibrosis and asthma. <i>Medicine and Science in Sports and Exercise</i> , 1999 , 31, 1242-9	1.2	15
47	Effect of oxygenation on breath-by-breath response of the genioglossus muscle during occlusion. <i>Journal of Applied Physiology</i> , 1991 , 71, 1231-6	3.7	14
46	Hispanic Infants with cystic fibrosis show low CFTR mutation detection rates in the Illinois newborn screening program. <i>Journal of Genetic Counseling</i> , 2012 , 21, 671-5	2.5	13
45	Elevated vascular endothelial growth factor is correlated with elevated erythropoietin in stable, young cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2011 , 46, 683-7	3.5	13
44	Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2012 , 47, 966-72	3.5	12
43	Sustained improvement in nutritional outcomes at two paediatric cystic fibrosis centres after quality improvement collaboratives. <i>BMJ Quality and Safety</i> , 2014 , 23 Suppl 1, i81-9	5.4	11
42	Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures. <i>BMJ Quality and Safety</i> , 2014 , 23 Suppl 1, i73-i80	5.4	11
41	ATS Consensus Statement: Research opportunities and challenges in pediatric pulmonology. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 776-80	10.2	11
40	Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. <i>Journal of Clinical and Translational Science</i> , 2018 , 2, 334-342	0.4	11
39	The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype. <i>Journal of Cystic Fibrosis</i> , 2018 , 17, 34-42	4.1	10
38	Bronchopulmonary dysplasia. Impact of surfactant replacement therapy. <i>Pediatric Clinics of North America</i> , 1998 , 45, 573-86	3.6	10
37	Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). <i>Journal of Cystic Fibrosis</i> , 2021 , 20, 810-819	4.1	10
36	Update in cystic fibrosis 2011. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 933-60.2	6.0	9

35	Immune modulation following aerobic exercise in children with cystic fibrosis. <i>International Journal of Sports Medicine</i> , 2000 , 21, 294-301	3.6	9
34	The demographics of adverse outcomes in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2019 , 54 Suppl 3, S74-S83	3.5	9
33	Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights. <i>Genes</i> , 2019 , 10,	4.2	8
32	Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics. <i>Physiological Genomics</i> , 2019 , 51, 27-41	3.6	8
31	Cystic fibrosis and portal hypertension: Distal splenorenal shunt can prevent the need for future liver transplant. <i>Journal of Pediatric Surgery</i> , 2019 , 54, 1076-1082	2.6	7
30	Differences in expression of cystic fibrosis in blacks and whites. <i>JAMA Pediatrics</i> , 1991 , 145, 94-7		7
29	Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 977-988	35.1	7
28	Cystic fibrosis year in review 2016. <i>Pediatric Pulmonology</i> , 2017 , 52, 1092-1102	3.5	6
27	Pediatric respiratory medicine--an international perspective. <i>Pediatric Pulmonology</i> , 2010 , 45, 14-24	3.5	6
26	Finding the relevance of antimicrobial stewardship for cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020 , 19, 511-520	4.1	5
25	Parental attitudes about exercise regarding their children with cystic fibrosis. <i>International Journal of Sports Medicine</i> , 1999 , 20, 334-8	3.6	5
24	Cystic fibrosis year in review 2018, part 1. <i>Pediatric Pulmonology</i> , 2019 , 54, 1117-1128	3.5	4
23	Postexercise immune correlates in children with and without cystic fibrosis. <i>Medicine and Science in Sports and Exercise</i> , 2000 , 32, 1997-2004	1.2	4
22	Update in pediatric lung disease 2012. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 293-7	10.2	3
21	Disparities in Parental Health Literacy at a Pediatric Cystic Fibrosis Center. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2015 , 28, 55-59	0.8	3
20	Quantity not sufficient rates and delays in sweat testing in US infants with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2020 , 55, 3053-3056	3.5	3
19	Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study. <i>Pediatric Pulmonology</i> , 2021 , 56, 3758-3767	3.5	3
18	Combination lumacaftor and ivacaftor therapy for cystic fibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2016 , 4, 233-242	1.1	2

17	Ivacaftor therapy for cystic fibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 1225-1232	1.1	2
16	Wheezing or stridor: intrinsic and extrinsic lesions causing noisy breathing. <i>Allergy and Asthma Proceedings</i> , 1998 , 19, 81-4	2.6	2
15	Cystic fibrosis year in review 2019: Section 1 CFTR modulators. <i>Pediatric Pulmonology</i> , 2020 , 55, 3236-3243	3.5	2
14	Comment on Munck et al., Feb, 2021. <i>Journal of Cystic Fibrosis</i> , 2021 , 20, 717-718	4.1	2
13	Cystic fibrosis year in review 2018, part 2. <i>Pediatric Pulmonology</i> , 2019 , 54, 1129-1140	3.5	1
12	Antibiotic duration and changes in FEV are not associated with time until next exacerbation in adult cystic fibrosis: a single center study. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 160	3.5	1
11	Cystic fibrosis year in review 2017. <i>Pediatric Pulmonology</i> , 2018 , 53, 1307-1317	3.5	1
10	Designing trials for new cystic fibrosis modulators. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 484-486	35.1	1
9	2014 year in review: Cystic fibrosis. <i>Pediatric Pulmonology</i> , 2015 , 50, 1147-56	3.5	1
8	Update in pediatric lung disease 2011. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 30-4	10.2	1
7	Primary Snoring in Children 2005 , 263-267		1
6	Preferences for disclosing adverse childhood experiences for children and adults with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2021 , 56, 921-927	3.5	0
5	Primary Snoring 2014 , 209-214		
4	Pediatric Pulmonology year in review 2015: Part 4. <i>Pediatric Pulmonology</i> , 2016 , 51, 754-65	3.5	
3	Pancytopenia in a child with cystic fibrosis and severe copper deficiency: Insight from bone marrow evaluation. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29276	3	
2	A rare case of pancytopenia in a child with cystic fibrosis: Can copper cure it all?. <i>Pediatric Pulmonology</i> , 2022 , 57, 317-319	3.5	
1	Cystic Fibrosis Diagnosis, Genetics and Lifelong Effects 2022 , 146-160		